GLP/GIP-based obesity therapies (Lir Life Sciences)

N/A

Report date: 2026/04/10 20:01:49
NME

Base Information

Drug NameGLP/GIP-based obesity therapies (Lir Life Sciences)
Drug Alias NameN/A
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucose-Dependent Insulinotropic Polypeptide Receptor modulatorsGlucagon-like peptide 1 receptor agonists
TargetsGlucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon-like peptide 1 receptor
Therapy Area/IndicationsObesity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLir Life Sciences Corp
China Registration ClassN/A

Develop Information

Active CompaniesLir Life Sciences Corp
Inactive CompaniesN/A
Active IndicationsObesity
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A